October is Breast Cancer Awareness Month, and all of us at MediCann wish to shed light on this insidious disease that affects our wives, mothers, grandmothers, girlfriends and friends. As doctors and healers, we are scientifically and ethically committed to doing everything in our power to stamp out cancer in our lifetime. As family members of victims, we are emotionally invested in creating awareness in every corner of the earth to stimulate action and results.
The tangible takeaways of medical cannabis in the treatment of cancer are well documented, and can be a game changer in the healing process, especially when it comes to reducing nausea and inflammation. Cannabis also alleviates the side effects (nausea, headache, insomnia, and even arthritis) of the pharmaceutical drugs Femora and Tamoxifen, commonly used in treating breast cancer. But, the exciting news is that there has been significant new research about cannabis and its role in the shrinking of tumors.
From the California Pacific Medical Center Research Institute to Complutense University in Madrid, studies are revealing what cannabis specialists have suspected since the 1970s : Cannabis is more than safe, natural, medicine, it’s a miracle plant that has myriad uses in healing a multitude of diseases, in this case cancer.
Researchers at the Complutense University assessed, “…the anti-tumor potential of THC and JWH-133, a non-psychotropic CB2 receptor-selective agonist, in the treatment of ErbB2-positive breast tumors – a highly aggressive form of breast cancer that is typically unresponsive to standard therapies. Both Delta-9-tetrahydrocannabinol ... and JWH-133 ...reduce tumor growth [and] tumor number [in mice]. ... These results provide a strong preclinical evidence for the use of cannabinoid-based therapies for the management of ErbB2-positive breast cancer."
As well, scientists at the California Pacific Medical Center Research Institute researched and reported in the medical journal Breast Cancer Research and Treatment “that treatment of mice with breast cancer and lung metastases with cannabidiol (CBD) showed significant reduction in the primary tumor mass as well as the size and number of lung metastases. The CBD accomplishes this by regulating genes that control the proliferation and invasion of tumor cells.”
What’s going on here, and why did it take centuries for the truth about the benefits of medical cannabis to become a part of mainstream medical cancer research? Are research institutes finally seeing the light and funding legitimate studies to rival the trillions of dollars spent by large pharmaceutical companies in their quest for ‘the cure?’ And if medical cannabis, a relatively inexpensive plant to cultivate, was seriously studied, funded, and allowed to flourish as mainstream medicine, would it put more expensive (and less effective) treatments out of business? Let’s not forget, the healthcare industry relies on debilitating disease such as breast cancer to stay viable. One thing we are sure about: if Wall Street is investing in cannabis-like drugs, it won’t be long until it heads into the mainstream, and is classified, once again, as a legitimate medicine (as it was in centuries past).
But in the winding road to medical cannabis legitimacy, and the pace at which critical research can shed new light on the disease, we suffer the loss of time and lives.
All of us at MediCann believe that ‘sunlight is the best disinfectant’ to quote Louis Brandeis. Knowledge is power, and if we can all continue to shed this sunlight in the darker corners of ignorance, we can hopefully, together find a cure for breast cancer and wipe cancer off the face of the earth.
To survivors of breast cancer everywhere: we salute you, you are brave and courageous women.
To our departed mothers, grandmothers, wives, girlfriends and friends: we didn’t get to you in time, and for this, we are profoundly sorry. It’s now time for all of us to get to work…
Yours in health,
25 October, 2011
Dr. Jean Talleyrand
McAllister SD, et al. Breast Cancer Research and Treatment. California Pacific Medical Center Research Institute, San Francisco. Published online: 22Sept2010.